Minerva Neurosciences Inc (NERV) - Total Liabilities
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has total liabilities worth $348.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Minerva Neurosciences Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Minerva Neurosciences Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Minerva Neurosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NERV current and non-current assets.
Minerva Neurosciences Inc Competitors by Total Liabilities
The table below lists competitors of Minerva Neurosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asia Tech Image
TWO:4974
|
Taiwan | NT$1.50 Billion |
|
Webster Financial Corporation
NYSE:WBS
|
USA | $74.58 Billion |
|
Shuttle Inc
TW:2405
|
Taiwan | NT$809.85 Million |
|
EGH Acquisition Corp. Class A Ordinary Shares
NASDAQ:EGHA
|
USA | $7.12 Million |
|
Finward Bancorp
NASDAQ:FNWD
|
USA | $1.85 Billion |
|
Invicta
JSE:IVT
|
South Africa | ZAC4.15 Billion |
|
KORE Group Holdings Inc
NYSE:KORE
|
USA | $587.62 Million |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
USA | $730.09 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Minerva Neurosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NERV net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Minerva Neurosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual total liabilities of Minerva Neurosciences Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $238.72 Million | +279.90% |
| 2024-12-31 | $62.84 Million | -26.38% |
| 2023-12-31 | $85.36 Million | +13.64% |
| 2022-12-31 | $75.11 Million | +8.63% |
| 2021-12-31 | $69.15 Million | +1293.06% |
| 2020-12-31 | $4.96 Million | -90.02% |
| 2019-12-31 | $49.72 Million | +1.74% |
| 2018-12-31 | $48.87 Million | -6.20% |
| 2017-12-31 | $52.10 Million | +93.25% |
| 2016-12-31 | $26.96 Million | -1.09% |
| 2015-12-31 | $27.26 Million | +60.80% |
| 2014-12-31 | $16.95 Million | +88.44% |
| 2013-12-31 | $9.00 Million | +4627.09% |
| 2012-12-31 | $190.29K | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more